Canine pulmonary vasoreactivity to serotonin: Role of protein kinase C and tyrosine kinase

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 272, Issue 2 41-2, 1997, Pages

  Barman, Scott A ^a   Pauly, James R ^a   Isales, Carlos M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

genistein; ketanserin; pulmonary capillary pressure; pulmonary vascular compliance; pulmonary vascular resistance; staurosporine; tyrphostin 25; vasoconstriction; verapamil; voltage dependent calcium channels

Indexed keywords

PROTEIN KINASE C; PROTEIN TYROSINE KINASE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL COMPLIANCE; BLOOD VESSEL REACTIVITY; DOG; FEMALE; LUNG BLOOD FLOW; MALE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

EID: 33750864913     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1997.272.2.h740     Document Type: Article

References (38)

1. Akiyama, T., J. Ishida, S. Nakagawa, H. Ogawara, S.-I. Watanabe, N. Itoh, M. Shibuya, and Y. Fukami. Genistein, a specific inhibitor of tyrosine-specific protein kinase. J. Biol. Chem. 262: 5592-5595, 1987.
2. Allison, R. C., K. T. Marble, E. M. Hernandez, M. I. Townsley, and A. E. Taylor. Attenuation of permeability lung injury after phorbol myristate acetate by verapamil and OKY-046. Am. Rev. Respir. Dis. 134: 93-100, 1986.
3. 2-serotonergic blockade. J. Pharmacol. Exp. Ther. 237: 548-552, 1986.
4. Consigny, P. M. Phorbol amplification of serotonin-induced arterial contractions is endothelium dependent. Am. J. Physiol. 257 (Heart Circ. Physiol. 26): H1174-H1179, 1989.
5. 2+ sensitivity for contraction of smooth muscle. Can. J. Physiol. Pharmacol. 72: 1434-1439, 1994.
6. El-Kashef, H. A., W. F. Hofman, and I. C. Ehrhart. Verapamil inhibition of serotonin-induced vasoconstriction in dog lung. J. Cardiovasc. Pharmacol. 15: 729-735, 1990.
7. Erspamer, V., and B. Asero. Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature Lond. 169: 800-801, 1952.
8. Geissler, J. F., P. Traxler, U. Regenass, B. J. Murray, J. L. Roesel, T. Meyer, E. McGlynn, A. Storni, and N. B. Lydon. Thiazolidine-diones: biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors. J. Biol. Chem. 265: 22255-22261, 1990.
9. Hakim, T. S. Identification of constriction in large versus small vessels using arterial-venous and the double-occlusion techniques in isolated canine lungs. Respiration 54: 61-69, 1988.
10. Hawker, J. R., Jr., and H. J. Granger. Tyrosine kinase inhibitors impair fibroblast growth factor signaling in coronary endothelial cells. Am. J. Physiol. 266 (Heart Circ. Physiol. 35): H107-H120, 1994.
11. Hikada, H., M. Inagaki, S. Kawamoto, and Y. Sasaki. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23: 5036-5041, 1984.
12. 2+ channels by serotonin 2 receptor stimulation in vascular smooth muscle cells. Am. J. Physiol. 268 (Heart Circ. Physiol. 37): H544-H549, 1995.
13. Hofman, W. F., and I. C. Ehrhart. Effects of cyclooxygenase inhibition on pulmonary vascular response to serotonin. J. Appl. Physiol. 62: 1192-1200, 1987.
14. Hollenberg, M. D. Tyrosine kinase pathways and the regulation of smooth muscle contractility. Trends Pharmacol. Sci. 15: 108-114, 1994.
15. Howell, J. B. L., S. Permutt, D. F. Proctor, and R. L. Riley. Effect of inflation of the lung on different parts of pulmonary vascular bed. J. Appl. Physiol. 16: 71-76, 1961.
16. Hyman, A. L. The direct effects of vasoactive agents on pulmonary veins. Studies of responses to acetylcholine, serotonin, histamine, and isoproterenol in intact dogs. J. Pharmacol. Exp. Ther. 168: 96-105, 1969.
17. 2+ mobilization and contraction in the porcine coronary artery. J. Physiol. Lond. 397: 410-419, 1988.
18. Kim, D., and W. N. Duran. Platelet-activating factor stimulates protein tyrosine kinase in hamster cheek pouch microcirculation. Am. J. Physiol. 268 (Heart Circ. Physiol. 37): H399-H403, 1995.
19. Leff, P., G. Martin, and J. M. Morse. Differential classification of vascular smooth muscle and endothelial cell 5-HT receptors by use of tryptamine analogs. Br. J. Pharmacol. 9: 321-331, 1987.
20. Linehan, J. H., C. A. Dawson, and D. A. Rickaby. Distribution of vascular resistance and compliance in a dog lung lobe. J. Appl. Physiol. 53: 158-168, 1982.
21. Linehan, J. H., C. A. Dawson, D. A. Rickaby, and T. A. Bronikowski. Pulmonary vascular compliance and viscoelasticity. J. Appl. Physiol. 61: 1802-1814, 1986.
22. McMahon, T. J., J. S. Hood, B. D. Nossaman, and P. J. Kadowitz. Analysis of responses to serotonin in the pulmonary vascular bed of the cat. J. Appl. Physiol. 75: 93-102, 1993.
23. Neely, C. F., D. Haile, and I. Matot. Tone-dependent responses of 5-hydroxytryptamine in the feline pulmonary vascular bed are mediated by two different 5-hydroxytryptamine receptors. J. Pharmacol. Exp. Ther. 264: 1315-1326, 1993.
24. Nishizuka, Y. Studies and perspectives of protein kinase C. Science Wash. DC 233: 305-312, 1986.
25. O'Brian, C. A., R. M. Liskamp, D. H. Solomon, and I. B. Weinstein. Inhibition of protein kinase C by tamoxifen. Cancer Res. 45: 2462-2465, 1985.
26. Orton, E. C., B. Raffestin, and I. F. McMurtry. Protein kinase C influences rat pulmonary vascular reactivity. Am. Rev. Respir. Dis. 141: 654-658, 1990.
27. Rippe, B., J. C. Parker, M. I. Townsley, N. A. Mortillaro, and A. E. Taylor. Segmental vascular resistances and compliances in dog lung. J. Appl. Physiol. 62: 1206-1215, 1987.
28. Ruegg, U. T., and G. M. Burgess. Staurosporine, K-252, and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol. Sci. 10: 218-220, 1989.
29. Sadoshima, J., N. Akaike, H. Kanaide, and M. Nakamura. Cyclic AMP modulates Ca-activated K channel in cultured smooth muscle cells of rat aortas. Am. J. Physiol. 255 (Heart Circ. Physiol. 24): H754-H759, 1988.
30. Sanders-Bush, E., M. Tsutsumi, and K. D. Burris. Serotonin receptors and phosphatidylinositol turnover. Ann. NY Acad. Sci. 600: 224-235, 1990.
31. Saxena, P. R., D. I. Wallis, W. Wouters, and P. Bevan (Editors). Cardiovascular Pharmacology of 5-Hydroxytryptamine: Prospective Therapeutic Applications. Dordrecht, The Netherlands: Kluwer Academic, 1990.
32. Shimamoto, Y., H. Shimamoto, C. Kwan, and E. E. Daniel. Differential effects of putative protein kinase C inhibitors on contraction of rat aortic smooth muscle. Am. J. Physiol. 264 (Heart Circ. Physiol. 33): H1300-H1306, 1993.
33. Semenchuk, L. A., and J. Di Salvo. Receptor-activated increases in intracellular calcium and protein tyrosine phosphorylation in vascular smooth muscle cells. FEBS Lett. 370: 127-130, 1995.
34. Tolloczko, B., L. Jia, and J. G. Martin. Serotonin-evoked calcium transients in airway smooth muscle cells. Am. J. Physiol. 269 (Lung Cell. Mol. Physiol. 13): L234-L240, 1995.
35. c,i in lung and skeletal muscle. J. Appl. Physiol. 61: 127-132, 1986.
36. 2 serotonergic receptors. J. Pharmacol. Exp. Ther. 218: 271-303, 1981.
37. Wang, H. Y., and E. Friedman. Central 5-hydroxytryptamine receptor-linked protein kinase C translocation: a functional postsynaptic signal transduction system. Mol. Pharmacol. 37: 75-79, 1990.
38. Yang, S. G., M. Saifeddine, A. Laniyonu, and M. D. Hollenberg. Distinct signal transduction pathways for angiotensin-II in guinea pig gastric smooth muscle: differential blockade by indomethacin and tyrosine kinase inhibitors. J. Pharmacol. Exp. Ther. 264: 958-966, 1993.